Akums Drugs and Pharmaceuticals Limited Earnings Summary — Q1 FY2027
Akums Drugs Reports Strong Q1 Performance with 71.6% YoY Profit Growth Post-IPO
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue grew 0.8% sequentially in Q1 FY2027.
- Revenue of ₹1,167 Cr is 13.9% higher year-on-year.
- Revenue has compounded at 9.9% annualised over the last 10 quarters.
- Revenue is at its highest level in 10 quarters.
- Net profit of ₹100 Cr is 57.5% above the same quarter last year.
- Profit growth is outpacing revenue growth, pointing to positive operating leverage.
- Net profit has compounded at 28.9% annualised across the period.
- Operating margin stands at 15.0% in Q1 FY2027.
- Operating margin expanded by 237 bps year-on-year.
- Over the last two years operating margin has expanded by 241 bps.
- PBT margin is 11.9%.
- Expense growth of 10.8% remained below revenue growth of 13.9%.
- Operating profit of ₹175 Cr is 35.4% higher year-on-year.
- Operating leverage continues to improve.
- 5 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 73/100 (Strong) on the latest 10 quarters.
- Business momentum remains positive heading into the next quarter.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Stable | 1,167 | 1,158 | 1,160 | 1,018 | 1,024 | 1,056 | 1,010 | 1,033 | 1,019 | 944 |
| Expenses | Stable | 992 | 1,006 | 1,013 | 923 | 895 | 962 | 889 | 912 | 891 | 941 |
| Operating Profit | Volatile | 175 | 152 | 147 | 94 | 129 | 94 | 121 | 121 | 128 | 3 |
| Operating Margin | Volatile | 15.0% | 13.1% | 12.7% | 9.3% | 12.6% | 8.9% | 12.0% | 11.7% | 12.6% | 0.3% |
| Other Income | Volatile | 30 | 34 | 16 | 32 | 27 | 26 | 19 | 17 | 7 | 10 |
| Interest | Volatile | 25 | 24 | 24 | 23 | 23 | 5 | 5 | 12 | 13 | 12 |
| Depreciation | Stable | 41 | 40 | 40 | 38 | 37 | 40 | 45 | 35 | 34 | 34 |
| Profit Before Tax | Volatile | 139 | 121 | 100 | 66 | 96 | 75 | 91 | 92 | 87 | -33 |
| Tax | Volatile | 38 | 40 | 32 | 23 | 31 | -74 | 25 | 25 | 26 | 7 |
| Net Profit | Improving | 100 | 85 | 66 | 41 | 63 | 148 | 65 | 65 | 60 | -41 |
| Net Margin | Volatile | 8.6% | 7.3% | 5.7% | 4.0% | 6.2% | 14.0% | 6.5% | 6.3% | 5.9% | -4.4% |
Key Takeaways
- Revenue grew by 13.9% YoY to ₹11,666 million, driven primarily by the core CDMO segment which saw robust volumes.
- Consolidated Net Profit surged 71.6% YoY to ₹1,109.78 million, benefiting from operational leverage and reduced finance costs post-IPO debt repayment.
- The company successfully utilized the entire ₹6,421.80 million of net IPO proceeds as of June 30, 2026, including full repayment of scheduled borrowings.
- CDMO segment remains the dominant contributor with ₹10,043 million in revenue, while the API segment continues to face profitability challenges with a quarterly loss of ₹81.46 million.
- A significant tax demand of ₹1,560.18 million for a block period (2018-2025) has been raised; management has filed an appeal and considers no adjustment necessary.
- The Board approved a total dividend of ₹3 per share (₹1 final + ₹2 special) for FY26 during the July 2026 AGM.
- Domestic branded formulations showed healthy segment results of ₹198.28 million, representing a steady growth path in the high-margin segment.
Management Guidance
Management remains focused on premiumization and scaling the CDMO platform. Following the IPO, the balance sheet has been significantly deleveraged, and the company is now targeting inorganic growth initiatives through acquisitions, as reflected in the reallocation of excess IPO funds.
Sentiment Shift
Improving
The substantial increase in net profit and successful utilization of IPO proceeds to clean up the balance sheet demonstrates a shift toward high-quality, deleveraged earnings growth.
Outlook
The outlook is positive as the company leverages its dominant 30%+ market share in India's CDMO space. Expansion into new categories and the integration of the Oriflame manufacturing business are expected to diversify revenue streams, though the unresolved tax litigation remains a moderate overhang.
From the Annual Report (Key Quotes)
“The Company has fully utilised the net IPO proceeds of ₹6,421.80 million towards the objects of the issue.”
“Management is of the view that no adjustments are required... for such [tax] demand based on legal assessment.”
“The business and operations of the Company continued without any disruptions [following search and seizure operations].”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Akums Drugs and Pharmaceuticals Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.
← Back to Akums Drugs and Pharmaceuticals Limited AI analysis